Afficher la notice abrégée

Sotrovimab to Prevent Severe COVID-19 in High-Risk Patients Infected with Omicron BA.2

dc.rights.licenseopenen_US
dc.contributor.authorMARTIN-BLONDEL, Guillaume
dc.contributor.authorMARCELIN, Anne-Geneviève
dc.contributor.authorSOULIÉ, Cathia
dc.contributor.authorKAISARIDI, Sofia
dc.contributor.authorLUSIVIKA-NZINGA, Clovis
dc.contributor.authorDORIVAL, Céline
dc.contributor.authorNAILLER, Laura
dc.contributor.authorBOSTON, Anaïs
dc.contributor.authorMELENOTTE, Cléa
dc.contributor.authorCABIÉ, André
dc.contributor.authorCHOQUET, Christophe
dc.contributor.authorCOUSTILLÈRES, François
dc.contributor.authorMARTELLOSIO, Jean-Philippe
dc.contributor.authorGAUBE, Géraldine
dc.contributor.authorTRINH-DUC, Albert
dc.contributor.authorRONCHETTI, Anne-Marie
dc.contributor.authorPOURCHER, Valerie
dc.contributor.authorCHAUVEAU, Marie
dc.contributor.authorLACOMBE, Karine
dc.contributor.authorPEIFFER-SMADJA, Nathan
dc.contributor.authorHOUSSET, Pierre
dc.contributor.authorPERROT, Aurore
dc.contributor.authorPIALOUX, Gilles
dc.contributor.authorMARTIN, Aurélie
dc.contributor.authorDUBEE, Vincent
dc.contributor.authorDEVAUX, Mathilde
dc.contributor.authorFREY, Jérôme
hal.structure.identifierCentre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorCAZANAVE, Charles
dc.contributor.authorLIBLAU, Roland
dc.contributor.authorCARRAT, Fabrice
dc.contributor.authorYORDANOV, Youri
dc.date.accessioned2023-05-16T15:27:25Z
dc.date.available2023-05-16T15:27:25Z
dc.date.issued2022
dc.identifier.issn0163-4453en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182164
dc.description.abstractEnBefore the Omicron era, the neutralizing antibody targeting the SARS-CoV2 Spike protein Sotrovimab has been shown to reduce the risk of COVID-19-related hospitalization in patients who are at high risk for progression (1, 2). We recently showed that early administration of Sotrovimab in Omicron-infected patients with very high-risk for progression was associated with a low rate of COVID-19-related hospitalization within one month after treatment administration (3%), and with no death (1). However, the dominance of the Omicron sublineage BA.2 led health agencies to suspend Sotrovimab emergency use authorizations because of its lower neutralizing ability in vitro compared to BA.1 sublineage (3, 4). Clinical efficiency of Sotrovimab to prevent COVID-19 related complications in high-risk patients with mild-to-moderate COVID-19 Omicron BA.2 remains unknown. Our aim was to compare the clinical and virological outcomes of Omicron BA.1 and BA.2-infected patients with mild-to-moderate COVID-19 who received 500 mg of Sotrovimab IV to prevent COVID-19-related complications.
dc.language.isoENen_US
dc.title.enSotrovimab to Prevent Severe COVID-19 in High-Risk Patients Infected with Omicron BA.2
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jinf.2022.06.033en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Maladies infectieusesen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Maladies émergentesen_US
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologieen_US
bordeaux.journalJournal of Infectionen_US
bordeaux.pageE104-E108en_US
bordeaux.volume85en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue4en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-03777531
hal.version1
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Infection&rft.date=2022&rft.volume=85&rft.issue=4&rft.spage=E104-E108&rft.epage=E104-E108&rft.eissn=0163-4453&rft.issn=0163-4453&rft.au=MARTIN-BLONDEL,%20Guillaume&MARCELIN,%20Anne-Genevi%C3%A8ve&SOULI%C3%89,%20Cathia&KAISARIDI,%20Sofia&LUSIVIKA-NZINGA,%20Clovis&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
MFP_Jinf_2022_Martinblondel.pdf
Taille:
1.763Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée